Gerard T. Berry, BS, MD

Dr. Gerard T. Berry is currently the Director of the Metabolism Program at Boston Children’s Hospital where he recently received a Senior Scientist Award for his clinical research involving galactosemia. He is also leading Boston Children’s Hospital’s efforts to expand its clinical services and research for children with galactosemia. Dr. Berry was awarded a grant from the Galactosemia Foundation to study neurons derived from IPs cells following reprogramming of cultured skin fibroblasts obtained from patients with galactosemia. Dr. Berry is interested in transcriptomic and metabolomic differences in galactosemia neurons exposed to galactose stress vs. those that have undergone CRISPR gene corrections,and is establishing an international registry/database in RedCap of patients with galactosemia. An active proponent of expanded newborn screening, Dr. Berry has received numerous grants from the NIH for hiswork with galactosemia, and receives additional funding from The Manton Center to conduct basic andclinical research side-by-side for translation into new therapies.

Dr. Berry has served as Chair of the Newborn Screening Committee of the Society for Inherited Metabolic Diseases and Chair of the General Clinical Research Center Budget Subcommittee at the Children's Hospital of Philadelphia. He also served as Senior Physician of the Division of Metabolism and later became the Senior Physician of the Division of Endocrinology and Diabetes and the Division of Human Genetics and Molecular Diseases at the Children’s Hospital of Philadelphia. Dr. Berry has also served as the Vice Dean for Research at Jefferson Medical College. At Children’s National Medical Center in Washington, D.C., Dr. Berry has worked as the Director of Biochemical Genetics and the Molecular Diagnostic Laboratory and Chief of the Division of Metabolism. Additionally, he has worked as a medical staff member at Thomas Jefferson University, Georgetown University Hospital, Children's National Medical Center, and Pennsylvania Hospital. He has also been a member of the Division of Medical Genetics of the Department of Medicine at the University of Pennsylvania.

In addition, Dr. Berry has served as Professor of Pediatrics at the University of Pennsylvania School OfMedicine, Professor of Pediatrics at George Washington University School of Medicine and Health Sciences, and Professor of Biochemistry at Thomas Jefferson University.

Dr. Berry received his BS from the University of Notre Dame and his MD from Jefferson Medical College. He completed his residency in pediatrics at Thomas Jefferson University Hospital.


Tatiana Grishina, MD, PhD is the Head of the Chair of Clinical Immunology of the Moscow State Medico-Stomatological University. She is also a Science Advisory Board Member and Russian Oncology Advisor to Bach Pharma, Inc. and offers broad research experience in mechanisms of pathogenesis of immunodeficiency, autoimmune diseases, endocrinology and oncology.

Dr. Grishina has served as a professor in the Department of Clinical Immunology at Moscow State University of Medicine and Dentistry where she was later named the Clinical Immunology Chair. In addition, Dr. Grishina has worked for the Centre of Modern Medicine, Ltd. In Moscow. She is also a member of the International Society of Allergology and Immunology and the Russian Society of Allergology and Immunology.

Dr. Grishina received her BS and MD from Moscow Medical University. She received her PhD from the Russian Institute of Occupational Health and completed her postdoctoral fellowship studying the immunology of occupational lung diseases.


Dr. Paul K. Y. Wong is currently a professor in the Department of Carcinogenesis at The University of Texas M.D. Anderson Cancer Center in Austin, Texas. He is also a part of the Neurodegeneration Research Team at Bach Pharma, Inc.and has extensive research experience involving the mechanisms of retroviral-induced and defective gene-mediated neurodegeneration and cancer.

Dr. Wong has also served as an adjunct professor in the Graduate School of Biomedical Sciences at The University of Texas Health Science Center and the Department of Veterinary Microbiology at Texas A&M University. At The University of Texas at Austin, Dr. Wong has taught as an adjunct professor in the Department of Microbiology, the Institute of Molecular Biology, the Division of Pharmacology and Toxicology, and the Institute for Neuroscience. Through his many teaching appointments, Dr. Wong has won the Dean’s Teaching Excellence Award. In addition to authoring over 220 publications, in 1998 Dr.Wong co-edited and co-contributed chapters in a pivotal book with Dr. William S. Lynn entitled "Neuroimmuno-degeneration”, a term they also created to describe the diseases in which immune and neural cells die prematurely.

Dr. Wong received his BS in Microbiology, his MS in Animal Virology and Genetics, and his PhD in Viral Genetics from the University of Manitoba in Canada. He completed a postdoctoral appointment at the University of Western Ontario studying retrovirology and cancer.


Ashok K. Shetty, PhD, Professor with the Department of Molecular and Cellular Medicine at the Texas A&M College of Medicine and Associate Director of the Institute of Regenerative Medicine has been working with the Department of Defense (DoD), the National Institutes of Health (NIH) and Department of Veterans Affairs (DVA) continuously for over 20 years. Dr. Shetty recently concluded a 5-year study using Bach Pharma’s drug product Monosodium Luminol (MSL) testing the drug’s efficacy in enhancing brain function after injury, disease or aging.

Dr. Shetty developed a rat model for testing Gulf War Illness (GWI). His pre-clinical research using Bach's drug MSL, showed that MSL was able to promote neurogenesis to help relieve the related inflammation,abnormal neurogenesis, Chronic Oxidative Stress, in the Hippocampus region of the brain of the GWI rats. Due to Dr. Shetty’s promising research, the DoD will fund the Clinical Trials using Bach’s MSL in Veterans, as soon as the toxicology testing needed for the planned oral method of drug delivery is completed. Dr. Shetty plans on continuing his research using Bach’s drugs for other related neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).

Dr. Shetty received his PhD in Neuroscience at the All India Institute of Medical Sciences in New Delhi, India, followed by a Postdoc in Neuroscience, Alcohol and Brain Development at Montana State University. He went on to a Postdoc in Neuroscience at Duke University Medical Center in Durham, NC for Hippocampus Injury and Plasticity, Cell Therapy for Brain Injury, Neural Stem Cells.

Dr. Shetty received the Research Career Scientist Award, Department of Veterans Affairs for 2016-2018,and 2011-2016, and has been rated a “Highly Cited Scientist”, among the top 1% of scientists in the field of Neuroscience and Behavior by THOMPSON REUTERS from 2009-2016.